Analysis of Biomarkers and Association With Clinical Outcomes in Patients With Differentiated Thyroid Cancer: Subanalysis of the Sorafenib Phase III DECISION Trial.
Publication/Presentation Date
12-15-2019
Abstract
PURPOSE: The phase III DECISION trial (NCT00984282; EudraCT:2009-012007-25) established sorafenib efficacy in locally recurrent or metastatic, progressive, differentiated thyroid cancer (DTC) refractory to radioactive iodine. We conducted a retrospective, exploratory biomarker analysis of patients from DECISION.
EXPERIMENTAL DESIGN: Candidate biomarkers [15 baseline plasma proteins, baseline and during-treatment serum thyroglobulin, and relevant tumor mutations (
RESULTS: Plasma biomarker and thyroglobulin data were available for 395 of 417 (94.7%) and 403 of 417 (96.6%) patients, respectively. Elevated baseline VEGFA was independently associated with poor prognosis for progression-free survival [PFS; HR = 1.82; 95% confidence interval (CI), 1.38-2.44;
CONCLUSIONS: We identified biomarkers associated with poor prognosis in DTC, including elevated baseline VEGFA and thyroglobulin and the presence of
Volume
25
Issue
24
First Page
7370
Last Page
7380
ISSN
1557-3265
Published In/Presented At
Brose, M. S., Schlumbeger, M., Jeffers, M., Kappeler, C., Meinhardt, G., & Peña, C. E. A. (2019). Analysis of Biomarkers and Association With Clinical Outcomes in Patients With Differentiated Thyroid Cancer: Subanalysis of the Sorafenib Phase III DECISION Trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 25(24), 7370–7380. https://doi.org/10.1158/1078-0432.CCR-18-3439
Disciplines
Medicine and Health Sciences
PubMedID
31558473
Department(s)
Hematology-Medical Oncology Division
Document Type
Article